Plus Therapeutics Shares Exciting New Brain Cancer Data At 2024 Neurological Surgeons Meeting

Plus Therapeutics, Inc. (Nasdaq: PSTV) will showcase its data at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting, happening from September 28 to October 2 in Houston, Texas. As a clinical-stage pharmaceutical company, Plus focuses on developing targeted radiotherapeutics using advanced platform technologies to treat central nervous system cancers.

Glioblastoma multiforme (GBM) impacts roughly 15,000 individuals each year in the U.S., making it the most prevalent and aggressive form of brain cancer. Patients with GBM typically face a life expectancy of under 24 months, with a one-year survival rate of just 40% and a five-year survival rate of about 5%. 

Currently, there is no definitive standard of care for recurrent GBM, and existing treatments offer only limited benefits while posing severe side effects that constrain dosing and long-term use. Nearly 90% of GBM patients experience a recurrence of the tumor at or near the original site, yet there are no FDA-approved therapies for recurrent or progressive cases that significantly prolong survival.

Plus Therapeutics, Inc. is at the forefront of clinical-stage pharmaceutical innovation, focusing on developing specialized radiotherapeutics for challenging central nervous system cancers. The company leverages cutting-edge techniques, including image-guided beta radiation and targeted drug delivery, to potentially improve patient outcomes. 

Its pipeline features promising candidates for recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Plus Therapeutics has established a robust supply chain through strategic partnerships to support the development, manufacturing, and eventual commercialization of its therapies. The company operates out of major cancer research centers in Austin and San Antonio, Texas, under the guidance of a highly skilled leadership team.